232 related articles for article (PubMed ID: 21615749)
1. Complement (C1q) fixing solid-phase screening for HLA antibodies increases the availability of compatible platelet components for refractory patients.
Fontaine MJ; Kuo J; Chen G; Galel SA; Miller E; Sequeira F; Viele M; Goodnough LT; Tyan DB
Transfusion; 2011 Dec; 51(12):2611-8. PubMed ID: 21615749
[TBL] [Abstract][Full Text] [Related]
2. C1q-fixing human leukocyte antigen assay in immunized renal patients: correlation between Luminex SAB-C1q and SAB-IgG.
Llorente S; Boix F; Eguia J; López M; Bosch A; Martinez H; Gonzalez MJ; López-Hernández R; Salgado G; Moya-Quiles MR; Campillo JA; García-Alonso AM; Minguela A; Jimeno L; Alvarez-López MR; Muro M
Transplant Proc; 2012 Nov; 44(9):2535-7. PubMed ID: 23146446
[TBL] [Abstract][Full Text] [Related]
3. Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beads.
Chen G; Sequeira F; Tyan DB
Hum Immunol; 2011 Oct; 72(10):849-58. PubMed ID: 21791230
[TBL] [Abstract][Full Text] [Related]
4. Technical Limitations of the C1q Single-Antigen Bead Assay to Detect Complement Binding HLA-Specific Antibodies.
Taylor CJ; Kosmoliaptsis V; Martin J; Knighton G; Mallon D; Bradley JA; Peacock S
Transplantation; 2017 Jun; 101(6):1206-1214. PubMed ID: 27306532
[TBL] [Abstract][Full Text] [Related]
5. Comparison Between Total IgG, C1q, and C3d Single Antigen Bead Assays in Detecting Class I Complement-Binding Anti-HLA Antibodies.
Moreno Gonzales MA; Mitema DG; Smith BH; Schinstock CA; Stegall MD; Wakefield LL; Henderson NA; DeGoey SR; Kreuter JD; Gandhi MJ
Transplant Proc; 2017 Nov; 49(9):2031-2035. PubMed ID: 29149956
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of platelet-specific antibodies and efficacy of crossmatch-compatible platelet transfusions in refractory patients.
Jia Y; Li W; Liu N; Zhang K; Gong Z; Li D; Wang L; Wang D; Jing Y; Wang J; Shan X
Transfus Med; 2014 Dec; 24(6):406-10. PubMed ID: 25327352
[TBL] [Abstract][Full Text] [Related]
7. C1q-binding anti-HLA antibodies do not predict platelet transfusion failure in Trial to Reduce Alloimmunization to Platelets study participants.
Jackman RP; Lee JH; Pei R; Bolgiano D; Lebedeva M; Slichter SJ; Norris PJ
Transfusion; 2016 Jun; 56(6):1442-50. PubMed ID: 27079754
[TBL] [Abstract][Full Text] [Related]
8. Clinical relevance of pretransplant anti-HLA donor-specific antibodies: does C1q-fixation matter?
Crespo M; Torio A; Mas V; Redondo D; Pérez-Sáez MJ; Mir M; Faura A; Guerra R; Montes-Ares O; Checa MD; Pascual J
Transpl Immunol; 2013 Dec; 29(1-4):28-33. PubMed ID: 23907088
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the C1q-Binding Ability and the IgG1-4 Subclass Profile of Preformed Anti-HLA Antibodies by Solid-Phase Assays.
Navas A; Molina J; Agüera ML; Guler I; Jurado A; Rodríguez-Benot A; Alonso C; Solana R
Front Immunol; 2019; 10():1712. PubMed ID: 31428086
[TBL] [Abstract][Full Text] [Related]
10. Investigation of Anti-HLA Antibodies of Highly Sensitized Patients by Single Antigen Bead and C1q Tests.
Ayna TK; Koçyİğİt AÖ; Soypaçaci Z; Tuğmen C; Pirim I
Transplant Proc; 2019 May; 51(4):1024-1026. PubMed ID: 31101164
[TBL] [Abstract][Full Text] [Related]
11. Systematic comparison of four cell- and Luminex-based methods for assessment of complement-activating HLA antibodies.
Lachmann N; Todorova K; Schulze H; Schönemann C
Transplantation; 2013 Mar; 95(5):694-700. PubMed ID: 23354296
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal management with crossmatch-compatible platelets for refractory patients: alloimmunization, response to transfusion, and clinical outcomes (CME).
Wiita AP; Nambiar A
Transfusion; 2012 Oct; 52(10):2146-54. PubMed ID: 23113654
[TBL] [Abstract][Full Text] [Related]
13. Persistent strong anti-HLA antibody at high titer is complement binding and associated with increased risk of antibody-mediated rejection in heart transplant recipients.
Zeevi A; Lunz J; Feingold B; Shullo M; Bermudez C; Teuteberg J; Webber S
J Heart Lung Transplant; 2013 Jan; 32(1):98-105. PubMed ID: 23142561
[TBL] [Abstract][Full Text] [Related]
14. Determinants of C1q binding in the single antigen bead assay.
Schaub S; Hönger G; Koller MT; Liwski R; Amico P
Transplantation; 2014 Aug; 98(4):387-93. PubMed ID: 24918611
[TBL] [Abstract][Full Text] [Related]
15. Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation.
Lee PC; Ozawa M
Clin Transpl; 2007; ():219-26. PubMed ID: 18642453
[TBL] [Abstract][Full Text] [Related]
16. Posttransfusion platelet count increments after ABO-compatible versus ABO-incompatible platelet transfusions in noncancer patients: an observational study.
Pavenski K; Warkentin TE; Shen H; Liu Y; Heddle NM
Transfusion; 2010 Jul; 50(7):1552-60. PubMed ID: 20210928
[TBL] [Abstract][Full Text] [Related]
17. Detection of immunoglobulin G human leukocyte antigen-specific alloantibodies in renal transplant patients using single-antigen-beads is compromised by the presence of immunoglobulin M human leukocyte antigen-specific alloantibodies.
Kosmoliaptsis V; Bradley JA; Peacock S; Chaudhry AN; Taylor CJ
Transplantation; 2009 Mar; 87(6):813-20. PubMed ID: 19300182
[TBL] [Abstract][Full Text] [Related]
18. C1q assay for the detection of complement fixing antibody to HLA antigens.
Chen G; Tyan DB
Methods Mol Biol; 2013; 1034():305-11. PubMed ID: 23775744
[TBL] [Abstract][Full Text] [Related]
19. Comparison of HLA antibody identification methods for the selection of platelet products for HLA-mediated platelet refractory patients.
Pedini P; Hubert L; Baudey JB; Etienne JM; Basire A; Vey N; Chiaroni J; Chabrières C; Ladaique P; Picard C
HLA; 2024 Jan; 103(1):e15276. PubMed ID: 37947374
[TBL] [Abstract][Full Text] [Related]
20. HLA antibody specification using single-antigen beads--a technical solution for the prozone effect.
Schnaidt M; Weinstock C; Jurisic M; Schmid-Horch B; Ender A; Wernet D
Transplantation; 2011 Sep; 92(5):510-5. PubMed ID: 21869744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
